Skip to content
lifestyle.claritypointe.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Angelini Ventures
Angelini Ventures and EIB Co-lead $58 Million Series A Financing in Rouge Therapeutics to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
October 6, 2026
EIB and Angelini Ventures’ Partnership Reaches €48.5 Million in Investments
September 16, 2026
Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
June 3, 2026